期刊
LUNG CANCER
卷 71, 期 1, 页码 82-88出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2010.04.008
关键词
Lung cancer; Chemotherapy; Platinum-agents; AKT; Clinical outcomes
资金
- National Cancer Institute (NCI) [R01 CA111646, P50 CA070907, R01 CA055769, R25T CA57730]
- NATIONAL CANCER INSTITUTE [P50CA070907, R25CA057730, R01CA127219, R01CA111646, R01CA111922, R01CA055769] Funding Source: NIH RePORTER
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related deaths. The effect of the PI3K/PTEN/AKT/mTOR signaling pathway on cancer treatment, including NSCLC, has been well documented. In this study, we analyzed associations between genetic variations within this pathway and clinical outcomes following platinum-based chemotherapy in 168 patients with stage IIIB (wet) or stage IV NSCLC. Sixteen tagging SNPs in five core genes (PIK3CA. PTEN, AKT1, AK72, and FRAP1) of this pathway and identified SNPs associated with development of toxicity and disease progression. We observed significantly increased toxicity for patients with PIK3CA:rs2699887 (OR: 3.86, 95% Cl: 1.08-13.82). In contrast, a SNP in PTEN was associated with significantly reduced risk for chemotherapeutic toxicity (OR: 0.44, 95% Cl: 0.20-0.95). We identified three SNPs in AKT1 resulting in significantly decreased risks of distant progression in patients carrying at least one variant allele with HRs of 0.66 (95% Cl: 0.45-0.97), 0.52 (95% Cl: 0.35-0.77), and 0.62 (95% Cl: 0.42-0.91) for rs3803304, rs2498804, and rs1130214, respectively. Furthermore, these same variants conferred nearly 2-fold increased progression-free survival times. The current study provides evidence that genetic variations within the PI3K/PTEN/AKT/mTOR signaling pathway are associated with variation in clinical outcomes of NSCLC patients. With further validation, our findings may provide additional biomarkers for customized treatment of platinum-based chemotherapy for NSCLC. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据